AIMM Accelerates Antibody Work with Pharma Partnership
By Nuala Moran
Tuesday, November 20, 2012
LONDON Dutch start-up AIMM Therapeutics NV has inked a deal with a pharma partner, providing the means to ramp up development of its novel antibody platforms, and has attracted a leading immunologist and former head of the Novartis Institute for Biomedical Research, Jan de Vries, as CEO to spearhead that effort.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.